Table 2

Cox models for achievement of complete remission, for progression/relapse, and for development of acute and chronic GVHD

VariableMultivariable analyses
Achievement of CR
Progression/relapse
HR (95% CI)PHR (95% CI)P
Development of chronic GVHD* 0.80 (0.43-1.47) .47 0.85 (0.51-1.42) .54 
Age† 0.96 (0.92-1.00) .05 1.08 (1.03-1.13) < .01 
IgG myeloma 0.77 (0.45-1.30) .33 0.61 (0.35-1.06) .08 
International Staging System 3 0.66 (0.22-1.98) .46 1.39 (0.69-2.79) .35 
Disease in remission‡ at allografting 2.20 (1.18-4.08) .03 0.30 (0.15-0.62) < .01 
 
VariableMultivariable analyses
Achievement of CR
Progression/relapse
HR (95% CI)PHR (95% CI)P
Development of chronic GVHD* 0.80 (0.43-1.47) .47 0.85 (0.51-1.42) .54 
Age† 0.96 (0.92-1.00) .05 1.08 (1.03-1.13) < .01 
IgG myeloma 0.77 (0.45-1.30) .33 0.61 (0.35-1.06) .08 
International Staging System 3 0.66 (0.22-1.98) .46 1.39 (0.69-2.79) .35 
Disease in remission‡ at allografting 2.20 (1.18-4.08) .03 0.30 (0.15-0.62) < .01 
 
Development of acute GVHD
Development of chronic GVHD
HR (95% CI)PHR (95% CI)P
CD3+ cells/kg recipient weight† 0.98 (0.81-1.18) .85 1.05 (0.97-1.13) .23 
CD34+ cells/kg recipient weight† 1.12 (1.04-1.21) < .01 1.03 (0.94-1.13) .55 
Age† 1.03 (0.98-1.09) .25 1.05 (1.01-1.10) .02 
Female donor 2.11 (1.00-4.45) .05 1.06 (0.54-2.08) .86 
Development of acute GVHD
Development of chronic GVHD
HR (95% CI)PHR (95% CI)P
CD3+ cells/kg recipient weight† 0.98 (0.81-1.18) .85 1.05 (0.97-1.13) .23 
CD34+ cells/kg recipient weight† 1.12 (1.04-1.21) < .01 1.03 (0.94-1.13) .55 
Age† 1.03 (0.98-1.09) .25 1.05 (1.01-1.10) .02 
Female donor 2.11 (1.00-4.45) .05 1.06 (0.54-2.08) .86 

Ig indicates immunoglobulin.

*

Time-dependent variable.

†

Continuous variable.

‡

Defined as VGPR and CR.

View Large